The AeroEclipse* II BAN is the most significant advancement in the history of small volume nebulizers, generating aerosol only in response to the patient's inspiratory maneuver. Since virtually no aerosol is produced during exhalation or at rest, clinicians can be confident that the dose prescribed is the dose delivered.

Posted in Published Studies, AEROECLIPSE*, COPD